Small-firm drugs are valued at an average of $2.16 billion, with preclinical risk-adjusted net value of $50 million and discovery-stage expected cost of $38 million, derived from market responses to announcements.
Next, let N0(t) and N2(t) be the number of drugs in the development stage and for which the firms applied for approval at time t, respectively
1 Pith paper cite this work. Polarity classification is still indexing.
1
Pith paper citing it
fields
econ.GN 1years
2022 1verdicts
UNVERDICTED 1representative citing papers
citing papers explorer
-
Valuing Pharmaceutical Drug Innovations
Small-firm drugs are valued at an average of $2.16 billion, with preclinical risk-adjusted net value of $50 million and discovery-stage expected cost of $38 million, derived from market responses to announcements.